特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者临床研究

doi:10.3969/j.issn.1672-5069.2020.04.026

摘要/Abstract

摘要： 目的探讨应用特利加压素联合腹水浓缩回输术治疗肝硬化并发难治性腹水患者的临床效果。方法 2017年5月～2019年10月解放军联勤保障部队第901医院感染病科诊治的肝硬化并发顽固性腹水患者54例,采用随机数字表法将患者分为观察组(n=27)和对照组(n=27)。对照组患者接受腹水浓缩回输术治疗,观察组在对照组治疗的基础上联合应用特利加压素治疗1周,观察两组肝肾功能、体质量、腹围、腹水和尿量的变化。结果在观察结束时,观察组和对照组腹围分别为(86.3±4.3)cm和(89.8±6.4)cm(P＜0.05),腹水深度分别为(31.5±8.4)mm和(53.3±9.4)mm(P＜0.05),血清胆红素水分别为(60.8±9.8)μmol/L和(71.5±8.7)μmol/L(P＜0.05),白蛋白水平分别为(33.3±3.0)g/L和(30.0±3.1)g/L(P＜0.05),尿素氮分别为(6.8±1.8)μmol/L和(9.8±2.8)μmol/L(P＜0.05),血清肌酐分别为(104.5±14.4)μmol/L和(133.8±15.3)μmol/L(P＜0.05),24 h尿量分别为(1088.3±285.9)mL和(1385.9±337.9)mL(P＜0.05),差异显著;观察组和对照组住院日分别为(28.8±3.7)d和(38.5±8.3)d(P＜0.05);腹水浓缩分别进行了(4.3±1.4)次和(10.7±3.2)次(P＜0.05),差异显著。结论应用特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者能减少腹水量、改善肝肾功能、缩短住院日,值得进一步验证。

关键词: 肝硬化, 顽固性腹水, 特利加压素, 腹水浓缩回输术, 治疗

Abstract: Objective To analyze the clinical effect of terlipressin combined with ascites concentration and reinfusion on refractory ascites patients with cirrhosis. Methods 54 cirrhotic patients with obstinate ascites were divided into observation group (n = 27) and control group (n = 27) from May 2017 to October 2019. The control group was treated with ascites concentration and reinfusion, and the observation group was treated with terlipressin on the basis of the control group. Results At the end of 14 day observation, the abdominal circumferences of patients in observation and control groups were (86.3±4.3) cm and (89.8±6.4) cm, the depth of ascites were (31.5±8.4) mm and (53.3±9.4) mm, serum bilirubin levels were (60.8±9.8) μmol/L and (71.5±8.7) μmol / L, serum albumin levels were (33.3±3.0) g / L and (30.0±3.1) g / L, serum BUN were (6.8±1.8) μmol / L and (9.8±2.8) μmol / L, sCr were (104.5±14.4) μmol / L and (133.8±15.3) μmol / L, significantly different between the two groups (P<0.05), and the 24 h urine volume were (1088.3±285.9)mL and (1385.9±337.9) mL, the hospital stays were (28.8±3.7) d and (38.5±8.3) d, and the ascites concentration and reinfusion were (4.3±1.4) times and (10.7±3.2) times, respectively, significantly different between the two groups (P<0.05). Conclusion The application of terlipressin combined with ascites concentration and reinfusion could reduce the amount of ascites, improve the functions of liver and kidney, shorten the length of hospital stay, and needs further investigation.

Key words: Liver cirrhosis, Refractory ascites, Terlipressin, Ascites concentration and reinfusion, Therapy

陈照林, 董静, 宋海燕, 刘波, 张骏飞. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者临床研究[J]. 实用肝脏病杂志, 2020, 23(4): 556-559.

Chen Zhaolin, Dong Jing, Song Haiyan, et al. Clinical observation of terlipressin combined with ascites concentration and reinfusion in the treatment of patients with refractory ascites[J]. Journal of Practical Hepatology, 2020, 23(4): 556-559.

参考文献

[1]Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med,2016, 375(8):767-777.
[2]Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet,2014, 383(9930):1749-1761.
[3]赵文敏,曾阿娟,范春蕾,等. 特利加压素治疗肝硬化并发顽固性腹水合并肾功能不全的疗效及安全性分析. 北京医学,2019,41(6):451-454.
[4]Zhang X, Wang SZ, Zheng JF, et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol,2014,20(32):11400-114005.
[5]Korean Association for the Study of the Liver (KASL). KASL Clinical Practice Guidelines for Liver Cirrhosis: Ascites and related complications. Clin Mol Hepatol,2018,24(3):230-277.
[6]Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int,2018,12(Suppl 1):122-134.
[7]Kozaki K, IInuma M, Takagi T,et al. Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial, 2016,20(4):36-82.
[8]戚虎昶,凌静,卢芳芳. 特利加压素临床研究进展. 解放军药学学报,2012,28(2):169-172.
[9]Papaluca T, Gow P. Terlipressin: Current and emerging indications in chronic liver disease. J Gastroenterol Hepatol,2018,33(3):591-598.
[10]Kalambokis NG, Tsiakas I, Christaki M, et al. Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. Eur J Gastroenterol Hepatol,2018,30(6):659-667.
[11]中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南. 实用肝脏病杂志,2018,21(1):21-31.
[12]Wang LK, An XF, Wu XL, et al. Doppler myocardial performance index combined with plasma B-type natriuretic peptide levels as a marker of cardiac function in patients with decompensated cirrhosis.Medicine (Baltimore),2018,97(48):e13302.
[13]张雅敏,门贺伟,杨龙,等. 特利加压素对大鼠70％肝切除后残肝再生的影响及其机制. 中华实验外科杂志,2014,31(8):1721-1724.
[14]王淑珍,丁惠国. 肝硬化并发顽固性腹水新的治疗模式及理念. 中华肝脏病杂志,2017,25(4):249-253.
[15]Appenrodt B, Lammert F. Renal failure in patients with liver cirrhosis: Novel classifications, biomarkers, treatment. Visc Med,2018,34(4):246-252.
[16]Huang YY, Sun JY, Wang JY, et al. Terlipressin resolves ascites of cirrhotic rats through downregulation of aquaporin 2. J Int Med Res, 2012,40(5):1735-1744.
[17]程丹颖,万钢,欧蔚妮,等. 特利加压素联合白蛋白治疗肝硬化急性肾损伤的临床疗效观察. 中华肝脏病杂志,2019,27(9):704-707.
[18]Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology, 2016,150(7):1579-1589.
[19]Koichi K, Masahiro I, Tomoyuki T, et al. Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial, 2016,20(4):376-382.
[20]Ristanto A, Caltabiano ML. Psychological support and well-being in post-bariatric surgery patients. Obes Surg,2019,29(2):739-743.